Pylarify was Lantheus Holdings’s largest product and service line in fiscal 2025, bringing in $989.12M of $2.53B (39%).
| Product and Service | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pylarify | $527.41M | $851.30M | $1.06B | $989.12M | |||||||||
| Total Radiopharmaceutical Oncology | — | — | — | $989.12M | |||||||||
| Definity | $244.99M | $279.77M | $317.79M | $330.25M | |||||||||
| D E F I N I T Y | — | — | — | — | |||||||||
| Technelite | $88.86M | $87.37M | $95.49M | $86.80M | |||||||||
| Techne Lite | — | — | — | — | |||||||||
| Other Nuclear | — | — | — | — | |||||||||
| Other | — | — | — | — | |||||||||
| Other Products | — | — | — | — | |||||||||
| Product Revenue, Net | — | — | — | — | |||||||||
| Neuraceq | — | — | — | $51.45M | |||||||||
| Xenon | — | — | — | — | |||||||||
| Strategic Partnerships & Other Revenue | $46.87M | $51.88M | $38.18M | $59.38M | |||||||||
| Other Precision Diagnostics | $22.83M | $22.98M | $24.23M | $24.62M | |||||||||
| Other Radiopharmaceutical Oncology | $4.10M | $3.13M | $384.00K | — | |||||||||
| License & Royalty Revenues | — | — | $9.13M | — | |||||||||
| Rebates & Allowances | — | — | — | — | |||||||||
| Total | $935.06M | $1.30B | $1.54B | $2.53B |
Lantheus Holdings brought in $2.53B from its seven product and service lines in fiscal 2025, the year ended December 31, 2025. Lantheus Holdings regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $1.54B. Pylarify was the largest at $989.12M (39.1%), ahead of Total Radiopharmaceutical Oncology at $989.12M (39.1%) and Definity at $330.25M (13.0%). The other four lines brought in $222.25M combined.
Compared with fiscal 2024, Strategic Partnerships & Other Revenue grew fastest, up 55.5% to $59.38M, while Technelite fell the most, down 9.1% to $86.80M.
Lantheus Holdings began breaking out Neuraceq in fiscal 2025, when it brought in $51.45M. Lantheus Holdings stopped reporting License & Royalty Revenues ($9.13M in fiscal 2024) and Other Radiopharmaceutical Oncology ($384.00K in fiscal 2024) as separate lines.
United States was Lantheus Holdings’s largest region in fiscal 2025, bringing in $1.46B of $1.54B (95%).
| Geography | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| United States | $1.26B | $1.48B | $1.46B | ||||||
| U.S | — | — | — | ||||||
| Rest Of World | $34.28M | $49.22M | $82.73M | ||||||
| All Other | — | — | — | ||||||
| Canada | — | — | — | ||||||
| Total | $1.30B | $1.53B | $1.54B |
Lantheus Holdings brought in $1.54B from its two regions in fiscal 2025, the year ended December 31, 2025. That is less than the $2.53B it reports by product and service, so these regions do not cover all of its revenue. United States was the largest at $1.46B (94.6%), ahead of Rest Of World at $82.73M (5.4%).
Compared with fiscal 2024, Rest Of World grew 68.1% to $82.73M, while United States fell 1.7% to $1.46B.
U.S was Lantheus Holdings’s largest segment in fiscal 2018, bringing in $178.44M of $228.61M (78%).
| Segment | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 |
|---|---|---|---|---|---|---|
| U.S | $235.82M | $257.42M | $54.82M | $178.44M | ||
| Worldwide | — | — | $157.27M | — | ||
| International | $57.64M | $44.43M | $41.38M | $50.17M | ||
| Total | $293.46M | $301.85M | $253.47M | $228.61M |
Lantheus Holdings brought in $228.61M from its two segments in fiscal 2018, the year ended December 31, 2018. Lantheus Holdings regrouped these segments after fiscal 2017, so the total does not compare directly with that year's $253.47M. U.S was the largest at $178.44M (78.1%), ahead of International at $50.17M (21.9%).
Compared with fiscal 2017, U.S grew 225.5% to $178.44M and International grew 21.2% to $50.17M. From fiscal 2015 to 2018, combined revenue from these segments fell from $293.46M to $228.61M, a compound annual decline of 8.0%. U.S's share of the total fell from 80.4% to 78.1%.
Lantheus Holdings stopped reporting Worldwide as a separate segment after fiscal 2017, when it brought in $157.27M.
Lantheus Holdings (LNTH) reports its revenue by product and service, by geography and by segment. In fiscal 2025, Pylarify was its largest product and service line, bringing in $989.12M (39.1% of the total), followed by Total Radiopharmaceutical Oncology at $989.12M (39.1%).
Pylarify was Lantheus Holdings' largest product and service line in fiscal 2025, bringing in $989.12M, or 39.1% of the $2.53B total across its seven product and service lines.
United States was Lantheus Holdings' largest region in fiscal 2025, bringing in $1.46B, or 94.6% of the $1.54B total across its two regions.
U.S was Lantheus Holdings' largest segment in fiscal 2018, bringing in $178.44M, or 78.1% of the $228.61M total across its two segments.
Rest Of World grew faster than United States in fiscal 2025, up 68.1% from $49.22M to $82.73M. United States fell 1.7% to $1.46B.
Every figure comes from Lantheus Holdings' annual financial filings, as reported. Each line keeps the name Lantheus Holdings gives it, and years follow its fiscal calendar.
Lantheus Holdings' revenue by product and service goes back to fiscal 2013, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.